期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The plasminogen activating system in the pathogenesis of Alzheimer’s disease 被引量:4
1
作者 Manuel Yepes 《Neural Regeneration Research》 SCIE CAS CSCD 2021年第10期1973-1977,共5页
Dementia is a clinical syndrome that affects approximately 47 million people worldwide and is characterized by progressive and irreversible decline of cognitive,behavioral and sesorimotor functions.Alzheimer’s diseas... Dementia is a clinical syndrome that affects approximately 47 million people worldwide and is characterized by progressive and irreversible decline of cognitive,behavioral and sesorimotor functions.Alzheimer’s disease(AD)accounts for approximately 60–80%of all cases of dementia,and neuropathologically is characterized by extracellular deposits of insoluble amyloid-β(Aβ)and intracellular aggregates of hyperphosphorylated tau.Significantly,although for a long time it was believed that the extracellular accumulation of Aβwas the culprit of the symptoms observed in these patients,more recent studies have shown that cognitive decline in people suffering this disease is associated with soluble Aβ-induced synaptic dysfunction instead of the formation of insoluble Aβ-containing extracellular plaques.These observations are translationally relevant because soluble Aβ-induced synaptic dysfunction is an early event in AD that precedes neuronal death,and thus is amenable to therapeutic interventions to prevent cognitive decline before the progression to irreversible brain damage.The plasminogen activating(PA)system is an enzymatic cascade that triggers the degradation of fibrin by catalyzing the conversion of plasminogen into plasmin via two serine proteinases:tissue-type plasminogen activator(tPA)and urokinase-type plasminogen activator(uPA).Experimental evidence reported over the last three decades has shown that tPA and uPA play a role in the pathogenesis of AD.However,these studies have focused on the ability of these plasminogen activators to trigger plasmin-induced cleavage of insoluble Aβ-containing extracellular plaques.In contrast,recent evidence indicates that activity-dependent release of uPA from the presynaptic terminal of cerebral cortical neurons protects the synapse from the deleterious effects of soluble Aβvia a mechanism that does not require plasmin generation or the cleavage of Aβfibrils.Below we discuss the role of the PA system in the pathogenesis of AD and the translational relevance of data published to this date. 展开更多
关键词 Alzheimer’s disease amyloid precursor protein amyloidβ NEUROSERPIN plasmin plasminogen activating system plasminogen activator inhibitor-1 synapse tissue-type plasminogen activator urokinase-type plasminogen activator
下载PDF
基于MTHFR和PAI-1基因多态性的精准药学服务对妊娠期高血压的预防效果 被引量:1
2
作者 叶鸣 汪洋 +3 位作者 爱琳 李培君 吴金兰 朱和平 《中国临床药学杂志》 CAS 2023年第4期247-251,共5页
目的 探究临床药师精准药学服务(基于MTHFR和PAI-1基因多态性,协助临床医师为孕妇制定个体化叶酸剂量及疗程)对妊娠期高血压的预防效果。方法 从2020年10月至2022年1月就诊孕妇中筛选自愿进行MTHFR和PAI-1基因多态性检测60例作为观察组... 目的 探究临床药师精准药学服务(基于MTHFR和PAI-1基因多态性,协助临床医师为孕妇制定个体化叶酸剂量及疗程)对妊娠期高血压的预防效果。方法 从2020年10月至2022年1月就诊孕妇中筛选自愿进行MTHFR和PAI-1基因多态性检测60例作为观察组,选择同期进行定期产检未接受MTHFR和PAI-1基因多态性检测的孕妇60例作为对照组。对照组患者予以常规药学服务,观察组患者在对照组基础上实施精准药学服务(根据MTHFR和PAI-1基因多态性选择个体化叶酸剂量及疗程等)。比较2组孕妇孕中、晚期血压,孕晚期尿蛋白及血清同型半胱氨酸(Hcy)水平,以及各阶段叶酸服用依从性。结果 观察组孕晚期无孕妇收缩压>140mmHg和/或舒张压>90 mmHg,对照组5例有上述情况;观察组孕妇孕晚期收缩压、舒张压及血清Hcy水平均低于对照组(P <0.05);观察组叶酸服用依从性MMAS评分8分孕妇占比多于对照组(93.33%vs 45.00%,P <0.05);观察组孕晚期尿蛋白阳性发生率低于对照组(8.33%vs 20.00%,P <0.05)。结论 基于MTHFR和PAI-1基因多态性选择个体化叶酸剂量及疗程的精准药学服务可以有效预防妊娠期高血压的发生。 展开更多
关键词 5 10-亚甲基四氢叶酸还原酶 血浆纤溶酶原激活物抑制剂-1 基因多态性 精准药学服务 妊娠期高血压
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部